|Ms. Terrie J. Curran||Pres, CEO & Director||560.72k||N/A||1969|
|Dr. Azmi Nabulsi M.D., M.P.H.||Chief Operating Officer||608.73k||N/A||1960|
|Mr. Aditya Kohli Ph.D.||Chief Bus. Officer||319.65k||N/A||1989|
|Mr. Todd P. Branning||Chief Financial Officer||N/A||N/A||1971|
|Mr. Joseph Hand J.D.||Chief Admin. Officer||N/A||N/A||N/A|
|Mr. Lawrence Miller Esq., J.D.||Gen. Counsel & Sec.||N/A||N/A||N/A|
|Mr. Tom Harris||Head of Regulatory Affairs||N/A||N/A||N/A|
|Dr. Eckhard Leifke M.D., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Martin J. Gilligan||Chief Commercial Officer||N/A||N/A||N/A|
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 9; Compensation: 9.